Yellow fever is an acute febrile illness caused by a mosquito-borne flavivirus. The discovery that mosquitos were responsible for transmission and that the disease was preventable by vector control, as well as the development of an efficacious vaccine (in the 1930s) have reduced its public health impact. However, underutilization of vaccination and discontinuation of vector control measures have led to yellow fever outbreaks, affecting thousands of people in Africa and South America, and is a continued threat to people who travel to endemic regions without vaccination. An additional concern is that the vaccine has important contraindications, and the currently available doses are insufficient to immunize the populations under risk of contracting yellow fever. Specific antiviral chemotherapy would be an alternative to vaccination, however there is none yet available. Drug repurposing is one strategy that can speed up drug discovery and development and has been underexplored for yellow fever. Methods A high content screening assay for the discovery of anti-yellow fever compounds was developed and used to screen a library of pharmacologically compounds, which includes approved drugs and covers most signalling pathways and all major drug target classes. The same library was screened against cells infected with a serotype 2 of the dengue virus.
INTRODUCTION
Flavivirus is a large genus comprising more than 70 pathogenic viruses of different pathologies with significant public health impact in across the tropical world. Yellow fever virus (YFV) and dengue virus (DENV) are some of the most important human pathogenic flaviviruses, sharing the same vectors and causing similar symptoms, ranging from low fever and malaise in mild infections, to haemorrhage and rapid terminal events with shock and failure of various organs in haemorrhagic fever syndrome 1, 2 .
Yellow fever is endemic in several South American and African countries. It has been estimated that up to 1.7 million yellow fever cases occur in Africa each year, mostly in West African countries, resulting in 29,000-60,000 deaths 3, 4 . Since late 2016, yellow fever outbreaks have occurred in the Southeast region of Brazil, with 792 confirmed cases, including 274 deaths 5, 6 in about 12 months. The transmission of YFV occurs through the bite of mosquito vectors belonging to different species. Usually sporadic human infection occurs through occasional transmission of YFV from nonhuman primates to humans through mosquito vectors belonging to the sylvatic YFV cycle -from the Haemagogus and Sabethes genus in South America and the Aedes genus in Africa -when humans come into endemic jungle and forest areas 7, 8 . In the urban cycle, the ubiquitous vector Aedes aegypti is responsible for the humanto-human transmission. The disease can spread rapidly and affect thousands of individuals 8,9 . Yellow fever is often an acute disease with a range of clinical manifestations, including fever, bradycardia and leukopenia. In 25 to 50% of cases, the acute phase can progress to an intoxication stage characterized by high fever, haemorrhagic syndrome, jaundice and kidney disease, which can be fatal. The patients surviving the acute period enter the convalescence phase, characterized by prolonged weakness and fatigue that can last several weeks 3, 4, 10 . Thus, in addition to presenting high lethality rates, yellow fever also causes heavy socio-economic burden in afflicted populations.
The adoption of vector control measures in the early 20 th century, followed by the development of a very effective vaccine in the 1930s, have greatly reduced yellow fever occurrence and deaths over the past decades 4 . However, the yellow fever vaccine also presents important contraindications, as it may cause severe adverse effects, and current protocols do not recommend the yellow fever vaccine to be administered to elderly older than 60 years, pregnant and breastfeeding women and immunocompromised individuals 11 . Another issue is the vaccine production worldwide, as it currently amounts to 80 million doses/year, whereas there are more than 3 billion people currently living in risk areas where Aedes mosquitos are endemic, offering the potential for yellow fever (re)introduction 12, 13 . Furthermore, deforestation and poor urbanization, present in most endemic countries, combined with changes in global migration patterns, have created ideal conditions for outbreaks of urban yellow fever in previously disease-free areas 7 .
Given the current yellow fever scenario, a specific antiviral treatment would have considerable value for populations that cannot take the vaccine. Moreover, in the wake of an outbreak, an antiviral could be administered either as prophylaxis or at the onset of any symptoms that could be associated with the disease, as strong immunity (80% of protection) normally needs at least 10 days after vaccination to develop 11, 14 . However, there is still no antiviral or other specific chemotherapy for the treatment of YFV, and clinical management of disease involves only attenuation of symptoms and supportive care of patients 15 .
Despite the need, there are very few published studies of drug screening for yellow fever. One feasible and often-deployed strategy for drug discovery is drug repurposing or repositioning, which consists on finding new uses for known clinical and experimental drugs.
As several pharmacological, toxicity and formulation aspects are already known for these molecules, they can be more readily available for clinical trials when compared to novel drugs.
Here we report the development of the first high content screening assay for the discovery of inhibitors of YFV infection. This assay was used to screen a compound library of pharmacologically active compounds, including pre-clinical and clinical drugs. The same library was screened against dengue virus in an analogous assay, enabling the comparison of results and the search for broad-spectrum antiflaviviral drugs.
METHODOLOGY

Virus and cell culture
A yellow Fever viral strains 17D expressing the enhanced yellow fluorescent protein (eYFP) was constructed for the HCS assay. The Aedes albopictus C6/36 cell line, the human hepatome cell line Huh7 and dengue virus serotype 2 isolate (DENV2) were kindly provided by Dr. Amílcar Tanuri from Federal University of Rio de Janeiro. C6/36 cells were cultivated in Leibovitz L-15 media (L4386, Sigma-Aldrich) at 28 °C. Huh7 cells were cultivated in DMEM F-12 media (56498C, Sigma-Aldrich) at 37 °C, 5% CO 2 . In both cases the media was supplemented with 10% FBS (F0804, Sigma-Aldrich), 100 U/mL of Penicillin and 100 µg/mL of Streptomycin (P4333, Sigma-Aldrich). Viral propagation and quantification was performed as described 16 with exception of the viral titration, which was carried out in Huh7 cells.
Construction and recovery of YFV expressing the eYFP gene
A recombinant YFV expressing enhanced yellow fluorescent protein (eYFP) was constructed by homologous recombination in yeast, using the previously constructed pBSC-YFV17D-T7 plasmid, which contains the entire genome of YFV strain 17D. The insertion of eYFP into YFV genome was made according to the strategy described by Bonaldo et al, 2007 17 , who introduced the GFP gene between the E and NS1 genes of YFV strain 17D. The YFV-eYFP plasmid was assembly by yeast recombination of two PCR products and the Nar-I for in vitro RNA synthesis (Megascript, Ambion). RNA transcripts were electroporated into BHK-21 cells and virus replication was verified by indirect immunofluorescence e reporter gene expression, as described previously 18 .
Reference drug and compound library preparation
The reference drug Interferon α 2A ( 
Hit selection and activity confirmation in dose-response
RESULTS
Activity assay development with Yellow Fever Virus
The yellow fever 17D vaccinal strain expressing the yellow fluorescent protein (YFV-eYFP), constructed as depicted in Figure 1A , was adapted to a high content screening assay for assessment of antiviral activity of compounds. Four images were acquired from all conditions and processed with the High Content Analysis Software Harmony to determine the total number of cells, number of infected cells, ratio of infected cells, and mean signal of eYFP/AlexaFluor594 ( Figure S1 ). In preliminary studies, the optimal number of host cells per well, DMSO concentration, multiplicity of infection and the assay duration were determined ( Figure S2 and S3). The DENV2 assay was adapted, with minor changes, from the previously published methodology 19 . Huh7 cells grow as a monolayer and present a large cytoplasm that allow for improved quantification of viral infection intensity in the host cell ( Figure 1B ). The reference drug IFNα 2A was chosen for these assay, as it was previously reported to have broad spectrum anti-flaviviral activity 21 . The IFNα 2A antiviral activity and cell toxicities against YFV and DENV2 infection of Huh7 were determined by dose-response curves. Figure 1C shows the dose-response curves of the reference compound, with the percent normalized activity and cell ratio. It was observed that IFNα 2A showed inhibition of YFV and DENV2 infection in a dose-dependent manner. The reference compound did not present cytotoxicity even at very high concentration (5.2 nM). The EC 50 values obtained for YFV and DENV2 were 17.31 pM and 30.07 pM, respectively. 
Screening of the LOPAC 1280 to identify drugs that are effective against Yellow Fever virus and Dengue virus serotype 2
The YFV HCS assay was validated by means of screening the Library of Pharmacologically Active Compounds (LOPAC), containing 1280 compounds, at 10 µM. The library was screened in two independent runs, and the correlation coefficient (r) between the two runs was 0.85 for compounds and controls and 0.80 for compounds only (Figure 2A and Figure S4 ). The mean Z'-factor of the runs were 0.78 ± 0.14 (mean ± standard deviation) for run 1, and 0.92 ± 0.04 for run 2. The DENV2 HCS assay had been previously validated (data not shown), thus the LOPAC was screened a single time, also at 10 µM. The average Z'-factor for all plates was 0.97 ± 0.01 (mean ± standard deviation). As the YFV and DENV assays are similar (both use the same host cell and last for the same period of viral infection and compound exposure) and the screening in both deployed the same library, at the same concentration, a comparison of antiviral activity was undertaken in search for compounds that might have activity against both viruses. The compounds with antiviral activity > 50% and cell ratio > 0.5 were compared from both YFV and DENV screening. In the YFV screening, there were 88 compounds in this category, while this number was reduced to 18 compounds in the DENV screening ( Figure S5 ). Among those, only 12 compounds were in common against both viruses (data not shown). Altogether, the data highlight that anti-DENV are more difficult to obtain than anti-YFV hits, however, most compounds that display anti-YFV activity were also at least partially active against DENV2 (12 out of 18 hits), demonstrating that there is a good potential for the discovery of compounds with broad antiviral activity with this type of approach.
The top 27 YFV screening hits yielded normalized activity equal to or approximately 70% and host cell toxicity ≤ 20 ( Figure 2B ) and were selected for activity confirmation in doseresponse. The twenty-seven YFV primary hits were tested in dose-response, and 25 of them presented high antiviral activity. However, most presented cell toxicity at the higher concentrations (Table S1 ). To be progressed further into drug discovery, a screening hit compound should have an acceptable in vitro potency (usually EC 50 values < 10 µM) and sufficient selectivity toward the pathogen as opposed to mammalian cells (SI ≥ 10) 22 With exception of Brequinar, none of these compounds were previously reported as active against Yellow Fever virus, although they had all been reported as potential antiviral against other viruses, including at least one other flavivirus (Table 1) . Altogether, these data demonstrate these compounds have a good potential of being developed further as broadspectrum anti-flavivirals, and may represent valuable starting points for anti-yellow fever drug discovery programs.
DISCUSSION
Despite the severity of the diseases and the clear need for chemotherapy, the body of published research on antiviral agents for yellow fever is less substantial in comparison with the amount of work undertaken for other major arthropod-borne flaviviruses, such as dengue.
The first screening campaign to identify potential candidates with activity against YFV utilized a replicon-based HTS assay, which was used to screen 34,000 small molecule compounds and resulted in the discovery of two compounds (CCG-4088 and CCG-3394) that were active against YFV 40 . However, their antiviral efficacies in animal models have not been reported so far. Another campaign used dengue virus for a pilot screening of a small molecule library of 26,900 compounds. The screening resulted in 14 compounds that inhibit dengue virus replication, and only one, benzothiazolylphenyl urea, was selected to further studies. This compound also inhibited YFV replication, and animal studies showed that it was well-tolerated and protected 90% of YFV-infected hamsters from death, significantly reduced the viral load, and normalized liver function 41, 42 . High Content Screening, which utilizes automated microscopy and image analysis, is another cell-based strategy for the discovery of antivirals and was adapted in this work. HCS assays involve the treatment of cell lines infected with viruses, replicons or pseudoinfectious particles (PIPs), with small molecule or natural product compounds. In all cases, the selection of hits is based on the reduction of infection measured by a fluorescent reporter gene or by indirect immunofluorescence 19, 20, 43 . In the present work, the HCS assay developed covers the whole viral cycle, from entry, RNA synthesis and viral egress of the host cell, potentially exposing all druggable targets, including host molecules that participate in the viral infection process. We selected the top 20 compounds for each virus among the 1280 compounds, although, interestingly, there was little overlap in terms of antiviral activity between the top 20 most active compounds from each screen, with only two compounds presenting activity against both viruses. The inability of YFV hits to inhibit DENV2 infection (and vice-versa) can be attributed to intrinsic assay differences, of which the more likely are structural and functional differences of viral proteins, or differential use of host proteins and machinery, such as receptors and other proteins involved in signalling pathways. Conversely, the two compounds that showed antiviral activity in both screenings, U-73343 and Brequinar, are more likely to act on conserved viral proteins that regulate viral replication and assembly, such as NS3 protease and NS5 polymerase. These compounds have been previously described as having antiviral activity in other models, including HCV, another flavivirus, demonstrating their potential to be further explored as broad-spectrum antivirals.
Of the 27 selected anti-YFV compounds for activity confirmation in dose-response, only five were found to be sufficiently selective (ie., at least 10 times more active toward the virus than to the host cell) to merit further analysis of their potential as hits for optimization.
All these five selected compounds (Gant61, Benztropine mesylate, Brequinar, PF-429242 and U-73343) were previously describes as having antiviral activity against several viruses, including HCV, DENV2 and even YFV (in the case of Brequinar), further validating the HCS approach as a viable technology for the discovery of antivirals.
Gant61 inhibits the Hedgehog (HH) pathway by inhibiting the transcriptional activity of GLI1/2. The HH pathway regulates critical cell decisions, including proliferation and apoptosis and also modulates wound healing responses in liver tissue 44, 45 . A study found that higher levels of HH pathway activity was associated with cirrhosis and human hepatocellular carcinomas in patients with chronical viral hepatitis, and that the pathway inhibition reduced cell fibrogenesis, angiogenesis, and growth 46 . The treatment of HCV-infected primary fibroblast with Gant61 was able to counteract the fibrosis and also reduce HCV replication 23, 46 .
This pathway is also correlated with the pathological outcome of the severe form of the yellow fever, which includes direct viral cytopathic effect, necrosis and apoptosis of hepatocyte cells.
A therapeutic approach that blocks the mechanisms that trigger apoptosis, and in thesis, would decrease the pathogenesis of yellow fever, could protect the liver in severe cases of disease 47, 48 .
The reduction of YFV replication in our assay may be correlated with the apoptosis regulated through the HH pathway. However, Gant61 is still an experimental drug and more preclinical and clinical trials are necessary to understand its pharmacokinetics and toxicity 49 .
Benztropine mesylate is a muscarinic receptor antagonist used for symptomatic treatment of Parkinson's disease. This compound has been demonstrated to have antiviral activity against HCV. One study demonstrated that benztropine inhibits HCV infection by blocking an early event, downstream of virion attachment but preceding HCV RNA replication 50 . Another study reported that benztropine inhibits Marburg and Ebola virus entry through different classes of G protein-coupled receptors (GPCRs), including the muscarinic acetylcholine receptor 27 . It is known that different viruses use different strategies to hijack the GPCRs and the GPCR-activated signalling pathways. Although the entry through GPCR is not extensively described for flavivirus, Le Sommer et al. 2012 51 reported that two members of the G protein-coupled receptor kinase family (GRK2 and GRK4) are required for efficient propagation of flaviviruses and that a decrease in GRK2 level alters both virus entry and RNA genome amplification. As benztropine mesylate is an antagonist of the muscarinic receptor, a member of the GPCRs family, it can be speculated that this compound inhibits YFV entry by antagonizing muscarinic receptors.
Brequinar sodium salt hydrate has broad-spectrum antiviral activity against both positive-and negative-strand RNA viruses. Brequinar inhibits cellular dihydroxyorotate dehydrogenase (DHODH), the fourth enzyme in the de novo pyrimidine biosynthesis pathway, preventing the synthesis of uracil nucleotides, and, consequently, DNA and RNA synthesis.
The main antiviral mechanism of Brequinar is the depletion of intracellular pyrimidine triphosphate, thus impairing viral RNA replication 31, 33 . Long Yeo et al. 2015 52 found that Brequinar can potentiate interferon-stimulated response element (ISRE) activation induced by interferon. This result indicate that Brequinar can enhance exogenous IFN-induced ISRE activation. However, the in vitro efficacy did not translate into in vivo efficacy, because uridine uptake from diets replenish or maintain a high concentration of pyrimidine in the plasma, and therefore lowering the compound-mediated inhibition of viral replication 53 . Another problem is that resistance can develop, and could occur via various mechanisms 32 . Qing et al. 2010 33 shown that Brequinar has activity against a broad spectrum of viruses by reducing the RNA synthesis, but dengue virus developed resistance through mutations in the envelope protein or NS5 gene. So far, it was not approved for clinical use for viral diseases owing to a low therapeutic index 32 .
Subtilisin kexin isozyme-1/site-1 protease (SKI-1/S1P), a key regulator of the cholesterol and fatty acid and their metabolism, through the processing of the transcription factor sterol regulatory element-binding proteins (SREBPs). It also regulates endoplasmic reticulum (ER)-stress response through cleavage of ATF6 and is involved in the processing of probrain-derived neurotrophic factor 36, 54 . The amino-pyrrolidine amide compound PF-429242 efficiently blocked the activation of SREBP by blocking the SKI-1/S1P-mediated process in CHO, HepG2 and HEK293 cell cultures and in CD1 mice 55 34, 36 . Another study showed that in vitro selected PF-429242-DENV cultures have not replicated after five times sequential treatment with PF-429242. The intracellular levels of lipids reduced with the treatment, and viral propagation were not recovered by addition of exogenous lipids 34 . These observations potentially provide a possible approach for the effective treatment of YFV infection using PF-429242. In our assay the PF-429242 did not present activity against DENV2 (data not shown), and this divergence in activity levels is likely due to the assay specific methodology: PF-429242 was shown to impair dengue virion assembly and release, but did not interfere with viral replication and protein production; in the assay reported here, dengue viral levels are indirectly monitored through immunofluorescence of the E protein, and thus interference with protein levels is not expected with PF-429242.
Phospholipase C catalyse the hydrolysis of phosphatidylinositol (PI) into two intracellular messengers, diacylglycerol and inositol triphosphate (IP3), which mediate the activation of protein kinase C (PKC) and release of intracellular Ca 2+ , respectively. The compound U-73122 was originally described as a potent inhibitor of agonist-induced platelet aggregation by inhibiting PLC 56, 57 . The analogue U-73343 differs from U-73122 by the substitution of a maleimide group for the less electrophilic succinide group, which resulted in loss of its PLC inhibitory ability, and therefore its analogue U-73343 is usually deployed as a negative control 58 . Chami et al. 2006 59 reported calcium-signalling alterations related to the intracellular presence of complete virions or viral proteins. They showed that elevations of cytosolic calcium levels allowed an increased viral protein expression for HIV-1, viral replication for HBx, enterovirus 2B, HTLV-1 p12I, and EBV, viral maturation for rotavirus, viral release for enterovirus 2B and cell immortalization for EBV 39, 59 . Another study demonstrated that the DENV2 infection causes an increased expression of the PLC, which cleaves the viral non-structural protein 1 (NS1) on the surfaces of cells infected with DENV.
They suggested that the upregulation of PLC expression could induce an increase in the levels NS1 released from host cells and thereby contribute to the haemorrhagic symptoms characteristic of severe dengue 60 . Thus, while it is likely that U-73343 inhibits YFV and DENV infection through a similar or the same mechanism, and that it might involve PLC, it is not clear yet how it happens in molecular terms, and it would be interesting to determine U-73343 mechanism of action as it offers potential as a broad-spectrum antiflaviviral.
Flaviviruses exploit host cell pathways and machinery during their replicative life cycle, and the inhibition of these cellular processes might have an inhibitory effect on virus replication. Boldescu et al. 2017 32 summarized the findings of numerous compounds with broad-spectrum antiviral activity that have already been identified by target-specific or phenotypic assays. Most broad-spectrum antiflaviviral compounds target viral protease or polymerase, host targets that are exploited during entry and replication, and proteins involved in nucleoside biosynthesis. Some anti-YFV compounds herein described were previously reported as having activity against several viruses and can serve as a potential starting point for the development of antiviral chemotherapy for yellow fever and other viruses.
